Navigation Links
Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
Date:4/23/2013

onder genotype 1 HCV patients.

In addition, Janssen has entered into a non-exclusive collaboration with Vertex Pharmaceuticals to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen of simeprevir and Vertex's investigational nucleotide analogue polymerase inhibitor VX-135 for the treatment of HCV. As a first step, Janssen is conducting a drug-drug interaction (DDI) study with simeprevir and VX-135. Janssen also has plans to initiate a Phase 2 trial of an investigational interferon-free regimen with simeprevir, TMC647055 and Idenix's IDX719, a once-daily, pan-genotypic NS5A inhibitor, with and without ribavirin.

For additional information about simeprevir clinical trials, please visit www.clinicaltrials.gov.

About Hepatitis C

Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide and 350,000 people per year die from the disease globally. When left untreated, HCV can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure.

About Janssen R&D Ireland

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen R&D Ireland is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forw
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
2. Dr. Kevin Foley to Present DiscGenics Recent Findings at the Lumbar Spine Research Societys Annual Meeting
3. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
4. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
7. Proof of Concept Study Initial Findings
8. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
9. ENDECE Neural to Present Findings for Remyelination at 2013 Keystone Symposia on Multiple Sclerosis
10. New Findings Link Telehealth-Enabled Care Coordination with Reduced Mortality for Patients with Congestive Heart Failure
11. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
(Date:7/31/2015)... ... July 31, 2015 , ... ... a Balloon Sinuplasty website to inform potential Nashville area sinus sufferers ... can be used to determine if someone is a good candidate for Balloon ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error ... **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, ... helping drug, biologic and device firms reduce manufacturing errors by 50 percent or ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... announces I am Fine, an app invention that can help people during emergencies. ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Currently, there ...
(Date:7/30/2015)... ... July 30, 2015 , ... In an effort to provide the twenty ... making a change in his practice. , The decision will also allow him to ... Aggarwal will be transferring his in-patient admissions to the hospitalists at East Liverpool City ...
(Date:7/30/2015)... ... 30, 2015 , ... In a meaningful ritual intended to symbolize a final ... Center have created an addiction graveyard. Sharing this with the public comes at a ... Rocky Hudson . Hudson (1945-2015) fell in love with the desert when he moved ...
Breaking Medicine News(10 mins):Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... Referrals to palliative care programs come too late, ... Palliative care services, which help people who are seriously ... at most U.S. cancer centers, but many programs don,t ... show. , Dr. David Hui, of the University ...
... destroying the benign tumors , TUESDAY, March 16 ... to get rid of uterine fibroids, the noncancerous but ... research shows. , Uterine fibroids are a common condition ... prolonged, heavy menstrual bleeding that can be severe enough ...
... ... System for the equivalent cost of a few dermal filler injections. , ... Toronto, Ontario (PRWEB) March 16, ... announced the launch of VuMe, the company’s latest surgical imaging system geared towards in-clinic ...
... VEGAS , March 16 Passion Parties once again leads ... a 100 percent phthalate-free toy line. The organization made the announcement during ... the latest innovations in sexual health and wellness. Passion Parties is ... romance accessories. , ...
... 2007 that there might be lead in the signature bracelet -- that they give to supporters when they make a minimum $15.00 donation ... ... , , ... ...
... N.J. , March 16 Tickerspy ( http://www.tickerspy.com ... announced the creation of the Chinese Healthcare Stocks Index, which ... AOB ), Sinovac Biotech (Nasdaq: SVA ), Mindray Medical ... CMED ), WuXi PharmaTech (NYSE: WX ), ...
Cached Medicine News:Health News:Pain Relief Often Delayed for Cancer Patients 2Health News:A New Way to Zap Away Uterine Fibroids 2Health News:A New Way to Zap Away Uterine Fibroids 3Health News:ModiFace Launches VuMe in Southern Florida – the World's First Full-Featured Touch-Screen Cosmetic Surgery Imaging System 2Health News:ModiFace Launches VuMe in Southern Florida – the World's First Full-Featured Touch-Screen Cosmetic Surgery Imaging System 3Health News:Passion Parties Becomes First and Only Company to Exclusively Sell Phthalates-Free Toys 2Health News:Passion Parties Becomes First and Only Company to Exclusively Sell Phthalates-Free Toys 3Health News:Passion Parties Becomes First and Only Company to Exclusively Sell Phthalates-Free Toys 4Health News:An Update on Mel's Bracelet 2Health News:Tickerspy.com Announces New Stock Index Tracking Chinese Healthcare Stocks 2Health News:Tickerspy.com Announces New Stock Index Tracking Chinese Healthcare Stocks 3
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
Inquire...
... Rotor has a standard 1.5ml rotor and 6 ... Easy operation (no switches to mess with). Simply ... the plastic tab to open. Starts and stops ... 2000 x g. Only five inches in diameter. ...
Inquire...
Medicine Products: